Advertisement

Research Pipeline I: Topical Therapies

  • Bassel Mahmoud
  • Linda Stein Gold
Chapter

Abstract

Psoriasis is a common chronic inflammatory skin disease affected by both genetics and immune factors. This devastating disease has a huge impact on the quality of life of affected individuals and a pronounced economic burden on the society. Recent understanding of the immunopathogenesis of psoriasis has led to significant progress in its treatment. Many disease-related factors affect the choice of therapy. Mild psoriasis can generally be managed with topical medications, while moderate-to-severe psoriasis is conventionally treated with more aggressive systemic therapies. The ideal treatment should be cost-effective, provide long-term remission and exhibit few side effects. This chapter highlights topical therapies currently under development for psoriasis.

Keywords

Psoriasis Topical Pipeline AN2728 INCB18424 JAK kinase inhibitor Methotrexate 

References

  1. 1.
    Foundation/USA NP. http://psoriasis.org/research/drugs-in-development/pipeline. Accessed 27 Sept 2011.
  2. 2.
    Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53(1 Suppl 1):S94–100.PubMedCrossRefGoogle Scholar
  3. 3.
    Guenther LC, Ortonne JP. Pathophysiology of psoriasis: science behind therapy. J Cutan Med Surg. 2002;6(3 Suppl):2–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003;49(2 Suppl):S44–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197–204.PubMedCrossRefGoogle Scholar
  6. 6.
    Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9(6):461–7.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Owaki T, Asakawa M, Morishima N, et al. A role for IL-27 in early regulation of Th1 differentiation. J Immunol. 2005;175(4):2191–200.PubMedCrossRefGoogle Scholar
  8. 8.
    Shibata S, Tada Y, Kanda N, et al. Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol. 2010;130(4):1034–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Baeumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6:17–26.CrossRefGoogle Scholar
  10. 10.
    Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009;10(11):1236–42.PubMedGoogle Scholar
  11. 11.
    Freund Y, Alley M, Kimura R, et al. In vitro activity and mechanism of action of AN2728, a novel oxaborole in development for treatment of psoriasis. J Invest Dermatol. 2008;128 Suppl 1:Abs 89.Google Scholar
  12. 12.
    Clinicaltrials.gov. http://clinicaltrials.gov/ct2/show/NCT01029405?term=an2728&rank=1. Accessed 27 Sept 2011.
  13. 13.
    Beutner K, Gassmueller I, Marti D, Lathrop A. AN2728, a novel oxaborole in development for treatment of psoriasis, demonstrates significant activity in a micro plaque study. J Invest Dermatol. 2008;128 Suppl 1:Abs 367.Google Scholar
  14. 14.
    Biomas-pharma company World Wide Website. http://biomas-pharma.com/Page.asp?PiD=0.2&id=13. Accessed 27 Sept 2011.
  15. 15.
    Incyte company World Wide Website. http://incyte.com/drugs_product_pipeline.html. Accessed 27 Sept 2011.
  16. 16.
    Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med. 2007;13(3):242–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Duffin KC, Luchi M, Fidelus-Gort R, et al. JAK 1/Jak 2 inhibition: a novel mechanism in the treatment of chronic plaque psoriasis. Society for Investigative Dermatology Meeting, Atlanta, 2010.Google Scholar
  18. 18.
    Dermipsor company World Wide Website. http://dermi-psor.com. Accessed 27 Sept 2011.
  19. 19.
    Mediquest Therapeutics company World Wide Website. http://mqti.com/technology.cfm. Accessed 27 Sept 2011.
  20. 20.
    Clinicaltrials.gov. http://clinicaltrials.gov/ct2/show/NCT00666354. Accessed 27 Sept 2011.
  21. 21.
    Ortonne JP, Noerrelund KL, Papp K, et al. Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body. Eur J Dermatol. 2010;20(5):585–9.PubMedGoogle Scholar
  22. 22.
    Welichem Biotech Inc. company World Wide Website. http://welichem.com/wbi_1001.php. Accessed 27 Sept 2011.
  23. 23.
    Creabilis Therapeutics company World Wide Website. http://www.creabilis-sa.com/projects.php?id=2. Accessed 27 Sept 2011.
  24. 24.
    Clinicaltrials.gov. http://clinicaltrials.gov/show/NCT00995969. Accessed 27 Sept 2011.
  25. 25.
    Maruho C, Ltd., Chugai Pharmaceutical C, Ltd. Approval of a new indication for Oxarol® ointment/lotion (nonproprietary name: maxacalcitol), psoriasis vulgaris treatment topical products containing active vitamin D3, for extended treatment of palmoplantar pustulosis. http://maruho.co.jp/english/pdf/2008/0811oxarol_pr_eng.pdf. Accessed 27 Sept 2011.
  26. 26.
    Clinicaltrials.gov. http://clinicaltrials.gov/ct2/show/NCT01360944. Accessed 27 Sept 2011.

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Department of DermatologyHenry Ford HospitalDetroitUSA

Personalised recommendations